基本資料

投資策略

主要投资于全球制药、生物科技、保健服务、医疗技术及生命科学之企业（「医疗保健企业」），以期达到基金之回报目标。子基金之资产（不包括现金及与现金相当之财产）至少67%将投资于医疗保健企业之权益证券。此等证券之发行人可位于任何国家，包括新兴市场。可辅助持有债权证券、现金及约当现金。子基金可投资于可转让证券集体投资计画及其他集体投资计画。子基金可投资于任何货币之资产，且子基金之货币曝险可进行避险或参考基金指标进行管理。子基金可为避险目的及有效管理投资组合而投资于衍生性金融工具。

基金經理人

• Valder Dominic
• 資歷 1年(2022-10-05 至今)

• Fleiss Holly
• 資歷 1年(2022-06-09 至今)

• Ms. Fleiss is a Managing Director at JPMIM and a co-portfolio manager in the JPMorgan U.S. Equity Group. She has been with the firm since 2012.

• Cohen Matthew
• 資歷 8年(2015-01-05 至今)

• Matthew G. Cohen, M.D., managing director, is a research analyst in the U.S. Equity Group. An employee since 2005, Dr. Cohen has been portfolio manager since 2015 and a research analyst in the firm’s U.S. Equity Group since 2005. Before joining the firm, Matthew was a senior healthcare analyst at Medici Healthcare and a senior analyst covering medical products at Narragansett Asset Management, a New York-based healthcare hedge fund. Prior to that, Dr. Cohen was a resident surgeon in the Department of General Surgery at the North Shore University Hospital NYU School of Medicine. Matthew holds an M.B.A. from New York University Stern School of Business and an M.D. from McGill University in Montreal.

基金費用

聯絡資訊